Empagliflozin Improves Diastolic Function in a Nondiabetic Rodent Model of Heart Failure With Preserved Ejection Fraction.
ANP, atrial natriuretic peptide
DOCA, deoxycorticosterone acetate
GADPH, glyceraldehyde 3-phosphate dehydrogenase
HF, heart failure
HFpEF, heart failure with preserved ejection fraction
HFrEF, heart failure with reduced ejection fraction
LV, left ventricular
SGLT2i, sodium-glucose−linked co-transporter-2 inhibitor
UNX, uninephrectomy
diastole
heart failure with preserved ejection fraction
sodium-glucose−linked co-transporter-2 inhibitor
systole
Journal
JACC. Basic to translational science
ISSN: 2452-302X
Titre abrégé: JACC Basic Transl Sci
Pays: United States
ID NLM: 101677259
Informations de publication
Date de publication:
Feb 2019
Feb 2019
Historique:
received:
01
05
2018
revised:
13
11
2018
accepted:
14
11
2018
entrez:
9
3
2019
pubmed:
9
3
2019
medline:
9
3
2019
Statut:
epublish
Résumé
Recent studies send an unambiguous signal that the class of agents known as sodium-glucose-linked co-transporter-2 inhibitors (SGLT2i) prevent heart failure hospitalization in patients with type 2 diabetes. However, the mechanisms remain unclear. Herein the authors utilize a rodent model of heart failure with preserved ejection fraction (HFpEF), and demonstrate that treatment with the SGLT2i empagliflozin, reduces left ventricular mass, improving both wall stress and diastolic function. These findings extend the observation that the main mechanism of action of empagliflozin involves improved hemodynamics (i.e., reduction in preload and afterload) and provide a rationale for upcoming trials in patients with HFpEF irrespective of glycemic status.
Identifiants
pubmed: 30847416
doi: 10.1016/j.jacbts.2018.11.010
pii: S2452-302X(18)30298-5
pmc: PMC6390677
doi:
Types de publication
Journal Article
Langues
eng
Pagination
27-37Références
Circulation. 2001 Jan 16;103(2):319-24
pubmed: 11208696
J Am Coll Cardiol. 2004 Apr 21;43(8):1481-8
pubmed: 15093887
J Hypertens. 2005 Feb;23(2):401-9
pubmed: 15662229
Br J Pharmacol. 2005 Nov;146(6):846-53
pubmed: 16151437
N Engl J Med. 2006 Jul 20;355(3):260-9
pubmed: 16855266
Cardiovasc Res. 2007 Nov 1;76(2):280-91
pubmed: 17716638
Am J Physiol Heart Circ Physiol. 2008 Jul;295(1):H281-8
pubmed: 18487445
Circ Heart Fail. 2009 Mar;2(2):129-37
pubmed: 19808328
Circ Heart Fail. 2010 May;3(3):420-30
pubmed: 20176713
PLoS One. 2010 Mar 04;5(3):e9543
pubmed: 20209052
J Hypertens. 2011 Jun;29(6):1175-84
pubmed: 21505358
Curr Cardiol Rev. 2010 Nov;6(4):291-7
pubmed: 22043205
CMAJ. 2012 Oct 2;184(14):E765-73
pubmed: 22908143
J Transl Med. 2013 Aug 07;11:183
pubmed: 23919327
Am J Physiol Heart Circ Physiol. 2015 Nov;309(9):H1407-18
pubmed: 26342070
N Engl J Med. 2015 Nov 26;373(22):2117-28
pubmed: 26378978
Am J Physiol Heart Circ Physiol. 2016 Jul 1;311(1):H96-H106
pubmed: 27199132
Diabetes Care. 2016 Jul;39(7):1108-14
pubmed: 27289126
Cell Metab. 2016 Aug 9;24(2):200-2
pubmed: 27508868
Am J Pathol. 2017 Jan;187(1):80-90
pubmed: 27993241
Sci Rep. 2016 Dec 21;6:39551
pubmed: 28000751
N Engl J Med. 2017 Aug 17;377(7):644-657
pubmed: 28605608
Diabetes Care. 2018 Feb;41(2):356-363
pubmed: 29203583
JACC Basic Transl Sci. 2017 Aug 04;2(4):347-354
pubmed: 30062155
Diabetes. 2018 Nov;67(11):2443-2455
pubmed: 30150305
J Am Soc Nephrol. 1999 Jan;10 Suppl 11:S143-8
pubmed: 9892155